Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study
Open Access
- 2 April 2020
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (4) , e0230846
Abstract
The objective of this study was to characterize the demographic and clinical profile of RRMS patients receiving fingolimod in Spain, and to evaluate drug effectiveness and safety in clinical practice. This observational, retrospective, multicentre, nationwide study was performed at 56 Spanish hospitals and involved 804 RRMS patients who received oral fingolimod (0.5 mg) since November 2011, with a minimum follow-up of 12 months. The mean annualized relapse rate (ARR) in the year before fingolimod was 1.08 and the median EDSS was 3; patients were exposed to fingolimod for 2.2 years as average; regarding magnetic resonance imaging (MRI) activity, more than half of the patients had >20 lesions at baseline. Patients were previously treated with first-line injectable DMTs (60.3%), or natalizumab (31.3%), and 8.3% were naïve patients. Overall, the ARR significantly decreased to 0.28, 0.22 and 0.17 (74.1%, 79.7% and 83.5% of relative reduction, respectively) after 12, 24 and 36 months of treatment, P<0.001. The ARR of patients who switched from natalizumab to fingolimod was stable over the study. Most of the patients (88.7%) were free from confirmed disability and MRI activity (67.3%) after 24 months. The persistence after 12 months on fingolimod was 93.9%. The subgroups of patients analysed showed differential baseline demographic and clinical characteristics. The analysis of patients who received fingolimod in routine clinical practice confirmed adequate efficacy and safety, even for long-term treatment. The present data also confirmed the positive benefit/risk balance with fingolimod in real-world clinical practice setting.Keywords
This publication has 28 references indexed in Scilit:
- The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple SclerosisCNS Drugs, 2015
- Fingolimod: A Review of Its Use in Relapsing-Remitting Multiple SclerosisDrugs, 2014
- Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysisJournal of Medical Economics, 2014
- Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trialThe Lancet Neurology, 2014
- Multiple sclerosis is primarily a neurodegenerative diseaseJournal of Neural Transmission, 2013
- Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosisAnnals of Neurology, 2011
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- Multiple Sclerosis: An Immune or Neurodegenerative Disorder?Annual Review of Neuroscience, 2008
- Accumulation of irreversible disability in multiple sclerosis: From epidemiology to treatmentClinical Neurology and Neurosurgery, 2006